PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells

Journal of Molecular Endocrinology

Volumn 53, Issue 1, 2014, Pages 31-41

  Itsumi, Momoe ^a   Shiota, Masaki ^a   Yokomizo, Akira ^a   Takeuchi, Ario ^a   Kashiwagi, Eiji ^a   Dejima, Takashi ^a   Inokuchi, Junichi ^a   Tatsugami, Katsunori ^a   Uchiumi, Takeshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen receptor; E2F1; Phorbol 12 myristate 13 acetate; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CASPASE 3; ENZALUTAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR E2F1; ANDROGEN RECEPTOR ANTAGONIST; E2F1 PROTEIN, HUMAN; PHENYLTHIOHYDANTOIN; PROTEIN KINASE C; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LNCAP CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; THERAPY EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE C; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903594617     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-13-0303     Document Type: Article

References (40)

1. Afrasiabi E, Ahlgren J, Bergelin N & Törnquist K 2008 Phorbol 12-myristate 13-acetate inhibits FRO anaplastic human thyroid cancer cell proliferation by inducing cell cycle arrest in G1/S phase: evidence for an effect mediated by PKCd. Molecular and Cellular Endocrinology 292 26-35. (doi:10.1016/j.mce.2008.04.018)
2. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM & Choubey D 2007 Expression of androgen receptor is negatively regulated by p53. Neoplasia 9 1152-1159. (doi:10.1593/neo.07769)
3. Aziz MH, Manoharan HT, Sand JM & Verma AK 2007 Protein kinase C epsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer. Molecular Carcinogenesis 46 646-653. (doi:10.1002/mc.20356) deBonoJS, LogothetisCJ, Molina A, FizaziK, NorthS, Chu L, ChiKN, JonesRJ, Goodman OB Jr, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
4. von Burstin VA, Xiao L & Kazanietz MG 2010 Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) d translocation and preventing PKCd-mediated release of tumor necrosis factor-a. Molecular Pharmacology 78 325-332. (doi:10.1124/mol.110.064741)
5. Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P & Grant S 2001 The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Research 61 2583-2591.
6. Chen F 2012 JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Research 72 379-386. (doi:10.1158/0008-5472. CAN-11-1982)
7. Chen J, Giridhar KV, Zhang L, Xu S & Wang QJ 2011 A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-kB activities. Carcinogenesis 32 1198-1206. (doi:10.1093/carcin/bgr113)
8. Choi KC, Park S, Lim BJ, Seong AR, Lee YH, Shiota M, Yokomizo A, Naito S, Na Y & Yoon HG 2011 Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor. Biochemical Journal 433 235-244. (doi:10.1042/BJ20100980)
9. Cozzi SJ, Parsons PG, Ogbourne SM, Pedley J & Boyle GM2006 Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Research 66 10083-10091. (doi:10.1158/0008-5472. CAN-06-0348)
10. DeGregori J, Kowalik T & Nevins JR 1995 Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/ S-regulatory genes. Molecular and Cellular Biology 15 4215-4224
11. Gavrielides MV, Gonzalez-Guerrico AM, Riobo NA & Kazanietz MG 2006 Androgens regulate protein kinase Cd transcription and modulate its apoptotic function in prostate cancer cells. Cancer Research 66 11792-11801. (doi:10.1158/0008-5472.CAN-06-1139)
12. Gonzalez-Guerrico AM & Kazanietz MG 2005 Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase Cd. Journal of Biological Chemistry 280 38982-38991. (doi:10.1074/ jbc.M506767200)
13. Gonzalez-Guerrico AM, Meshki J, Xiao L, Benavides F, Conti CJ & Kazanietz MG2005 Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. Journal of Biochemistry and Molecular Biology 38 639-645. (doi:10.5483/BMBRep.2005.38.6.639)
14. Kashiwagi E, Shiota M, Yokomizo A, Itsumi M, Inokuchi J, Uchiumi T & Naito S 2012 Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer. Prostate 72 741-751. (doi:10.1002/pros.21478)
15. MacDonald I, Knox KA & Gordon J 1994 Stimulation of human B lymphocytes by phorbol esters reported to be selective in the protein kinase C isoforms they activate. Molecular Immunology 31 671-674. (doi:10.1016/0161-5890(94)90176-7)
16. Parker PJ, Bosca L, Dekker L, Goode NT, Hajibagheri N & Hansra G 1995 Protein kinase C (PKC)-induced PKC degradation: a model for downregulation. Biochemical Society Transactions 23 153-155.
17. Ryan CJ & Tindall DJ 2011 Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. Journal of Clinical Oncology 29 3651-3658. (doi:10.1200/JCO.2011.35.2005)
18. Sadar MD 2011 Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Research 71 1208-1213. (doi:10.1158/0008-5472.CAN_10-3398)
19. ScherHI, BeerTM, HiganoCS, Anand A, TaplinME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J et al. 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375 1437-1446. (doi:10.1016/S0140-6736(10)60172-9)
20. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
21. Sharifi N, Gulley JL & Dahut WL 2010 An update on androgen deprivation therapy for prostate cancer. Endocrine-Related Cancer 17 R305-R315. (doi:10.1677/ERC-10-0187)
22. Sharma A, YeowWS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK et al. 2010 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation 120 4478-4492. (doi:10.1172/JCI44239)
23. Shiota M, Yokomizo A & Naito S 2011a Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. Journal of Molecular Endocrinology 47 R25-R41. (doi:10.1530/JME-11-0018)
24. Shiota M, Yokomizo A, Fujimoto N & Naito S 2011b Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castrationresistant prostate cancer. Current Cancer Drug Targets 11 870-881. (doi:10.2174/156800911796798904)
25. Shiota M, Yokomizo A & Naito S 2011c Oxidative stress and androgen receptor signaling in the development and progression of castrationresistant prostate cancer. Free Radical Biology & Medicine 51 1320-1328. (doi:10.1016/j.freeradbiomed.2011.07.011)
26. Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y et al. 2011d Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocrine-Related Cancer 18 505-517. (doi:10.1530/ERC-11-0017)
27. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T & Naito S 2011e Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Radical Biology & Medicine 51 78-87. (doi:10.1016/j.freeradbiomed.2011.04.001)
28. Shiota M, Yokomizo A, Itsumi M, Uchiumi T, Tada Y, Song Y, Kashiwagi E, Masubuchi D & Naito S 2011f Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU International 108 E142-E149. (doi:10.1111/j.1464-410X.2010.09810.x)
29. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, Tatsugami K, Uchiumi T, Oda Y & Naito S 2012a Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. Journal of Urology 187 707-714. (doi:10.1016/j.juro. 2011.09.147)
30. Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K & Naito S 2012b Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. Journal of Urology 188 300-306. (doi:10.1016/j.juro.2012.02.2553)
31. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME & Rennie PS 2009 In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clinical Cancer Research 15 39-47. (doi:10.1158/1078-0432.CCR-08-1726)
32. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
33. Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z & Haimovitz-Friedman A 2005 Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. Journal of Biological Chemistry 280 23262-23272. (doi:10.1074/ jbc.M503701200)
34. Vigorito E, Plaza S, Mir L, Mongay L, Viñas O, Serra-Pagès C & Vives J 1999 Contributions of p53 and PMA to gamma-irradiation induced apoptosis in Jurkat cells. Hematology and Cell Therapy 41 153-161. (doi:10.1007/s00282-999-0153-0)
35. Wu GS 2004 The functional interactions between the p53 and MAPK signaling pathways. Cancer Biology & Therapy 3 156-161. (doi:10.4161/ cbt.3.2.614)
36. Xiao L, Eto M & Kazanietz MG 2009 ROCK mediates phorbol ester-induced apoptosis in prostate cancer cells via p21Cip1 up-regulation and JNK. Journal of Biological Chemistry 284 29365-29375. (doi:10.1074/ jbc.M109.007971)
37. Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ et al. 2012 ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14 74-83. (doi:10.1593/neo. 111436)
38. Yin L, Bennani-Baiti N & Powell CT 2005 Phorbol ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway. Journal of Biological Chemistry 280 5533-5541. (doi:10.1074/jbc.M405266200)
39. Yokomizo A, Shiota M, Kashiwagi E, Kuroiwa K, Tatsugami K, Inokuchi J, Takeuchi A & Naito S 2011 Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate 71 298-304. (doi:10.1002/pros.21243)
40. Zuckerman V, Wolyniec K, Sionov RV, Haupt S & Haupt Y 2009 Tumour suppression by p53: the importance of apoptosis and cellular senescence. Journal of Pathology 219 3-15. (doi:10.1002/path.2584)